End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4,183 MXN | +0.85% |
|
-.--% | +2.49% |
07-10 | Health Care Up in Anticipation of Deal Activity -- Health Care Roundup | DJ |
07-10 | FDA Reports Supply Interruptions for Becton Dickinson BD BACTEC Culture Media Bottles | DJ |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company is in debt and has limited leeway for investment
- With an expected P/E ratio at 32.37 and 28.69 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 3.94 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+2.49% | 66.67B | - | ||
-6.68% | 179B | C+ | ||
-5.20% | 100B | C | ||
-6.47% | 46.16B | B- | ||
+18.16% | 44.81B | B+ | ||
+9.74% | 44.38B | B- | ||
+14.01% | 29.53B | B | ||
+22.31% | 25.83B | A- | ||
-6.53% | 23.97B | A- | ||
+3.54% | 22.5B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- BDX Stock
- BDX * Stock
- Ratings Becton, Dickinson and Company